# HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

> **NCT06213519** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 69 (estimated)

## Conditions studied

- Peritoneal Metastases
- Gastric Cancer

## Interventions

- **DRUG:** S-1, Oxaliplatin sintilimab HIPEC

## Key facts

- **NCT ID:** NCT06213519
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06213519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06213519, "HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06213519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*